Defining ultrahigh-risk AL amyloidosis with VWF

Abstract

In this issue of Blood, Kastritis et al report the results of using von Willebrand factor antigen (VWF:Ag) to define an ultrahigh-risk group of patients with immunoglobulin amyloid light-chain (AL) amyloidosis.1 The accurate identification of these patients could help design future clinical trials desperately needed to define the best treatment of these patients.